Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 14.67
CEMP's Cash to Debt is ranked lower than
54% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. CEMP: 14.67 )
Ranked among companies with meaningful Cash to Debt only.
CEMP' s Cash to Debt Range Over the Past 10 Years
Min: 1.12  Med: 8.16 Max: No Debt
Current: 14.67
Equity to Asset 0.82
CEMP's Equity to Asset is ranked higher than
69% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CEMP: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
CEMP' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.75 Max: 0.82
Current: 0.82
0.48
0.82
F-Score: 4
Z-Score: -0.17
M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -672.95
CEMP's Operating margin (%) is ranked lower than
74% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. CEMP: -672.95 )
Ranked among companies with meaningful Operating margin (%) only.
CEMP' s Operating margin (%) Range Over the Past 10 Years
Min: -672.95  Med: -390.38 Max: -325.59
Current: -672.95
-672.95
-325.59
Net-margin (%) -678.68
CEMP's Net-margin (%) is ranked lower than
74% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. CEMP: -678.68 )
Ranked among companies with meaningful Net-margin (%) only.
CEMP' s Net-margin (%) Range Over the Past 10 Years
Min: -678.68  Med: -405.16 Max: -333.64
Current: -678.68
-678.68
-333.64
ROE (%) -62.91
CEMP's ROE (%) is ranked lower than
68% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. CEMP: -62.91 )
Ranked among companies with meaningful ROE (%) only.
CEMP' s ROE (%) Range Over the Past 10 Years
Min: -101.98  Med: -94.12 Max: -62.91
Current: -62.91
-101.98
-62.91
ROA (%) -49.46
CEMP's ROA (%) is ranked lower than
67% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. CEMP: -49.46 )
Ranked among companies with meaningful ROA (%) only.
CEMP' s ROA (%) Range Over the Past 10 Years
Min: -191.64  Med: -64.24 Max: -49.46
Current: -49.46
-191.64
-49.46
ROC (Joel Greenblatt) (%) -133712.31
CEMP's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. CEMP: -133712.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -133712.31  Med: -41875.95 Max: -18139.82
Current: -133712.31
-133712.31
-18139.82
EBITDA Growth (3Y)(%) 21.20
CEMP's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CEMP: 21.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CEMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.7  Med: -65.2 Max: 21.2
Current: 21.2
-67.7
21.2
EPS Growth (3Y)(%) 19.30
CEMP's EPS Growth (3Y)(%) is ranked higher than
74% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CEMP: 19.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CEMP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.3  Med: -67.2 Max: 19.3
Current: 19.3
-69.3
19.3
GuruFocus has detected 2 Warning Signs with Cempra Inc $CEMP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CEMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CEMP Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q1 2016

CEMP Guru Trades in Q1 2016

Jim Simons 30,330 sh (New)
George Soros 181,825 sh (New)
» More
Q2 2016

CEMP Guru Trades in Q2 2016

Jim Simons 205,300 sh (+576.89%)
George Soros Sold Out
» More
Q3 2016

CEMP Guru Trades in Q3 2016

Mario Gabelli 53,400 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VTVT, NAS:APEN, OTCPK:TYMI, NAS:RDHL, OTCPK:OGRMF, OTCPK:SPHRF, NAS:OPHT, NAS:MDGL, NAS:AGTC, NAS:CBMG, NAS:GNMX, NAS:DVAX, OTCPK:SIGA, NAS:NVLN, NAS:CLSD, NAS:CDTX, OTCPK:DGJI, NAS:ABUS, NAS:AVXL, OTCPK:PRMCF » details
Traded in other countries:9C1.Germany,
Cempra Inc is a clinical-stage pharmaceutical company. It develops antibiotics for acute care & community settings to meet critical medical needs in treatment of bacterial infectious diseases, respiratory tract & chronic staphylococcal infections.

Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the development of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide and the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.

Ratios

vs
industry
vs
history
P/B 0.86
CEMP's P/B is ranked higher than
93% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. CEMP: 0.86 )
Ranked among companies with meaningful P/B only.
CEMP' s P/B Range Over the Past 10 Years
Min: 0.71  Med: 6.52 Max: 20.33
Current: 0.86
0.71
20.33
P/S 10.15
CEMP's P/S is ranked higher than
52% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. CEMP: 10.15 )
Ranked among companies with meaningful P/S only.
CEMP' s P/S Range Over the Past 10 Years
Min: 8.36  Med: 47.09 Max: 76.39
Current: 10.15
8.36
76.39
EV-to-EBIT 0.92
CEMP's EV-to-EBIT is ranked higher than
90% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. CEMP: 0.92 )
Ranked among companies with meaningful EV-to-EBIT only.
CEMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.3  Med: -6.9 Max: 0.92
Current: 0.92
-26.3
0.92
EV-to-EBITDA 0.92
CEMP's EV-to-EBITDA is ranked higher than
91% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. CEMP: 0.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
CEMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.3  Med: -6.9 Max: 0.92
Current: 0.92
-26.3
0.92
Current Ratio 10.18
CEMP's Current Ratio is ranked higher than
77% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CEMP: 10.18 )
Ranked among companies with meaningful Current Ratio only.
CEMP' s Current Ratio Range Over the Past 10 Years
Min: 2.48  Med: 10.18 Max: 30.34
Current: 10.18
2.48
30.34
Quick Ratio 10.18
CEMP's Quick Ratio is ranked higher than
78% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CEMP: 10.18 )
Ranked among companies with meaningful Quick Ratio only.
CEMP' s Quick Ratio Range Over the Past 10 Years
Min: 2.48  Med: 10.18 Max: 30.34
Current: 10.18
2.48
30.34
Days Sales Outstanding 104.24
CEMP's Days Sales Outstanding is ranked lower than
73% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. CEMP: 104.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.37  Med: 75.96 Max: 104.24
Current: 104.24
56.37
104.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.90
CEMP's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. CEMP: -20.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CEMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -314.5  Med: -288.6 Max: -20.9
Current: -20.9
-314.5
-20.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.88
CEMP's Price/Net Cash is ranked higher than
97% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.31 vs. CEMP: 0.88 )
Ranked among companies with meaningful Price/Net Cash only.
CEMP' s Price/Net Cash Range Over the Past 10 Years
Min: 0.88  Med: 6.1 Max: 16.1
Current: 0.88
0.88
16.1
Price/Net Current Asset Value 0.86
CEMP's Price/Net Current Asset Value is ranked higher than
97% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. CEMP: 0.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.86  Med: 5.93 Max: 14.51
Current: 0.86
0.86
14.51
Price/Tangible Book 0.86
CEMP's Price/Tangible Book is ranked higher than
95% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. CEMP: 0.86 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMP' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.86  Med: 5.88 Max: 14.43
Current: 0.86
0.86
14.43
Price/Median PS Value 0.22
CEMP's Price/Median PS Value is ranked higher than
92% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CEMP: 0.22 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.03 Max: 1.53
Current: 0.22
0.21
1.53
Earnings Yield (Greenblatt) (%) 108.70
CEMP's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. CEMP: 108.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -156.22  Med: 0 Max: 308.91
Current: 108.7
-156.22
308.91

More Statistics

Revenue (TTM) (Mil) $15.87
EPS (TTM) $ -2.22
Beta0.83
Short Percentage of Float20.45%
52-Week Range $2.55 - 26.95
Shares Outstanding (Mil)52.38

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 17 34 57
EPS ($) -2.36 -0.94 -0.74 -0.25
EPS w/o NRI ($) -2.36 -0.94 -0.74 -0.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
Does Cempra Have The Next Blockbuster Drug? Jan 08 2015 

More From Other Websites
Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs Jan 11 2017
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 09 2017
Cempra to Present at J.P. Morgan Healthcare Conference Jan 04 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and... Jan 03 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cempra, Inc. of a Class Action Lawsuit... Jan 03 2017
Is the Options Market Predicting a Spike in Cempra (CEMP) Stock? Jan 03 2017
Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session Jan 03 2017
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Cempra, Inc. and... Dec 30 2016
Cempra: You Can Brag… Dec 30 2016
GPM Reminds Investors of the January 3 Deadline in the Class Action Lawsuit Against Cempra, Inc. Dec 30 2016
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate Dec 30 2016
Top Analyst Upgrades and Downgrades: Tesla Motors, Kate Spade, Xilinx, Yandex, Cempra and More Dec 30 2016
Blog Coverage Cempra's Stock Price Dropped Following US FDA Rejection of Its Pneumonia Drug Dec 30 2016
Cempra shares crater on concerns about delay in getting pneumonia drug approved Dec 30 2016
Cempra upgraded by Morgan Stanley Dec 30 2016
Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded Dec 30 2016
For Cempra, feasibility of FDA-suggested study yet to be determined Dec 29 2016
Cempra, xG Technology Slide into Thursday’s 52-Week Low Club Dec 29 2016
Nvidia (NVDA) Can’t Shake Citron, Cempra (CEMP) Slammed by FDA Rejection, Plus 3 Other Major... Dec 29 2016
Stocks Volatile After Trade Deficit Data; Oil Inventories Rise Dec 29 2016
Cempra Shares Get Halved After Receipt of CRL From the FDA Dec 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)